Evidence map›Paper›PMID 22527638›Full record

ArticleJournal of muscle research and cell motility2012

Pathogenic properties of the N-terminal region of cardiac myosin binding protein-C in vitro.

Suresh Govindan, Jason Sarkey, Xiang Ji, Nagalingam R Sundaresan, Mahesh P Gupta, Pieter P de Tombe, Sakthivel Sadayappan

Open access · greenAbstract read
In one paragraph

Article in Journal of muscle research and cell motility, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Cells · 2024
    Article
  3. Hypertrophic cardiomyopathy inThe journal of cardiovascular aging · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suresh GovindanDepartment of Cell and Molecular Physiology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA.
Jason Sarkey
Xiang Ji
Nagalingam R Sundaresan
Mahesh P Gupta
Pieter P de Tombe
Sakthivel Sadayappan
Loyola University Chicago · USUniversity of Chicago · US

Funding

Sarcomeric Modifications and Progressive Cardiac MaladaptationP01HL062426 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 2000 to 2020
$42.4M
TRAINING IN CELLULAR SIGNALLING IN THE CARDIOVASCULAR SYT32HL007692 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI SOLARO, R JOHN · 1990 to 2014
$8.5M
Fast myosin binding protein-C and cardiac contractility in heart failureR01HL105826 · NHLBI · UNIVERSITY OF CINCINNATI · PI SADAYAPPAN, SAKTHIVEL · 2011 to 2025
$4.5M
Activation of sirtuins to prevent adverse cardiac remodeling after CABGR01HL111455 · NHLBI · UNIVERSITY OF CHICAGO · PI GUPTA, MAHESH P · 2013 to 2016
$1.6M
Myosin Binding Protein C structure-function relationships in the failing heartP30HL101297 · NHLBI · LOYOLA UNIVERSITY CHICAGO · PI DE TOMBE, PIETER P. · 2009 to 2010
$703k
NHLBI NIH HHS HL007692NHLBI NIH HHS HL101297NHLBI NIH HHS HL62426NHLBI NIH HHS P01 HL062426NHLBI NIH HHS P30 HL101297NHLBI NIH HHS R01 HL105826NHLBI NIH HHS R01HL105826NHLBI NIH HHS R01 HL111455NHLBI NIH HHS T32 HL007692
6 · The paper itself

Abstract

Cardiac myosin binding protein-C (cMyBP-C) plays a role in sarcomeric structure and stability, as well as modulating heart muscle contraction. The 150 kDa full-length (FL) cMyBP-C has been shown to undergo proteolytic cleavage during ischemia-reperfusion injury, producing an N-terminal 40 kDa fragment (mass 29 kDa) that is predominantly associated with post-ischemic contractile dysfunction. Thus far, the pathogenic properties of such truncated cMyBP-C proteins have not been elucidated. In the present study, we hypothesized that the presence of these 40 kDa fragments is toxic to cardiomyocytes, compared to the 110 kDa C-terminal fragment and FL cMyBP-C. To test this hypothesis, we infected neonatal rat ventricular cardiomyocytes and adult rabbit ventricular cardiomyocytes with adenoviruses expressing the FL, 110 and 40 kDa fragments of cMyBP-C, and measured cytotoxicity, Ca(2+) transients, contractility, and protein-protein interactions. Here we show that expression of 40 kDa fragments in neonatal rat ventricular cardiomyocytes significantly increases LDH release and caspase 3 activity, significantly reduces cell viability, and impairs Ca(2+) handling. Adult cardiomyocytes expressing 40 kDa fragments exhibited similar impairment of Ca(2+) handling along with a significant reduction of sarcomere length shortening, relaxation velocity, and contraction velocity. Pull-down assays using recombinant proteins showed that the 40 kDa fragment binds significantly to sarcomeric actin, comparable to C0-C2 domains. In addition, we discovered several acetylation sites within the 40 kDa fragment that could potentially affect actomyosin function. Altogether, our data demonstrate that the 40 kDa cleavage fragments of cMyBP-C are toxic to cardiomyocytes and significantly impair contractility and Ca(2+) handling via inhibition of actomyosin function. By elucidating the deleterious effects of endogenously expressed cMyBP-C N-terminal fragments on sarcomere function, these data contribute to the understanding of contractile dysfunction following myocardial injury.

Indexed as

AcetylationActinsActomyosinAdenoviridaeAmino Acid SequenceAnimalsCalciumCardiac MyosinsCarrier ProteinsCell DeathCells, CulturedHeart VentriclesImmunoprecipitationL-Lactate DehydrogenaseMiceMolecular Sequence DataActinsActomyosinCalciumCardiac MyosinsCarrier ProteinsL-Lactate DehydrogenaseMyosin Binding Protein CPeptide Fragments

Identifiers

PMID22527638
PMCPMC3368277
OpenAlexW2004637620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.